| Medical and Health Sciences | Lifetime | 127 | US 72 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 31 | US 14 | 99.99 |
| Economics and Finance | 2021-2025 | 820 | US 231 | 96.69 |
| Surgery | Lifetime | 9 | US 4 | 99.99 |
| Cardiology and Cardiovascular Medicine | Lifetime | 226 | US 132 | 99.70 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 134 | US 75 | 99.57 |
| Cancer Research | Lifetime | 197 | US 103 | 98.89 |
| Epidemiology | Lifetime | 700 | US 359 | 99.09 |
| Immunology | Lifetime | 654 | US 335 | 97.99 |
| Nutrition and Dietetics | Lifetime | 635 | US 265 | 97.11 |
| Immunology and Allergy | Lifetime | 228 | US 91 | 96.48 |
| Surgery | 2021-2025 | 2 | US 1 | 99.99 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 45 | US 28 | 99.83 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 91 | US 46 | 98.71 |
| Cancer Research | 2021-2025 | 68 | US 24 | 96.92 |
| Econometrics and Quantitative Economics | 2021-2025 | 514 | US 117 | 97.11 |
| Epidemiology | 2021-2025 | 848 | US 306 | 91.59 |
| Nutrition and Dietetics | 2021-2025 | 366 | US 76 | 83.77 |
| Immunology | 2021-2025 | 768 | US 275 | 74.56 |
| Cancer, Lipids, and Metabolism | Lifetime | 6 | US 4 | 99.95 |
| Pharmaceutical Economics and Policy | Lifetime | 2 | US 2 | 99.78 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 10 | US 6 | 99.94 |
| Lipoproteins and Cardiovascular Health | Lifetime | 6 | US 3 | 99.96 |
| Lipid metabolism and disorders | Lifetime | 6 | US 3 | 99.79 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 20 | US 12 | 99.84 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 54 | US 24 | 99.78 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 20 | US 13 | 99.72 |
| Fatty Acid Research and Health | Lifetime | 45 | US 19 | 99.27 |
| Cell Adhesion Molecules Research | Lifetime | 112 | US 67 | 99.52 |
| Cardiovascular Disease and Adiposity | Lifetime | 120 | US 73 | 99.31 |
| Cardiovascular Function and Risk Factors | Lifetime | 580 | US 307 | 98.98 |
| Acute Myocardial Infarction Research | Lifetime | 344 | US 170 | 98.88 |
| Cardiac Imaging and Diagnostics | Lifetime | 745 | US 378 | 98.86 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 285 | US 118 | 98.62 |
| Diet and metabolism studies | Lifetime | 932 | US 393 | 98.40 |
| Blood Pressure and Hypertension Studies | Lifetime | 562 | US 233 | 98.39 |
| Cardiovascular Health and Disease Prevention | Lifetime | 464 | US 198 | 97.81 |
| Protease and Inhibitor Mechanisms | Lifetime | 378 | US 167 | 97.59 |
| Cholesterol and Lipid Metabolism | Lifetime | 239 | US 117 | 97.40 |
| Coronary Interventions and Diagnostics | Lifetime | 646 | US 268 | 98.20 |
| Cardiovascular Health and Risk Factors | Lifetime | 209 | US 122 | 97.14 |
| Heart Failure Treatment and Management | Lifetime | 607 | US 287 | 97.81 |
| Transplantation: Methods and Outcomes | Lifetime | 656 | US 377 | 96.97 |
| Diabetes Treatment and Management | Lifetime | 870 | US 322 | 97.10 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | Lifetime | 602 | US 269 | 95.25 |
| Aortic Thrombus and Embolism | Lifetime | 100 | US 49 | 91.54 |
| Biomarkers in Disease Mechanisms | Lifetime | 568 | US 152 | 85.51 |
| Apelin-related biomedical research | Lifetime | 913 | US 253 | 83.94 |
| GDF15 and Related Biomarkers | Lifetime | 521 | US 169 | 81.63 |
| Caveolin-1 and cellular processes | Lifetime | 926 | US 377 | 82.51 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 2 | US 1 | 99.90 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 2 | US 1 | 99.94 |
| Lipid metabolism and disorders | 2021-2025 | 1 | US 1 | 99.81 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 14 | US 4 | 99.64 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 11 | US 4 | 99.68 |
| Pharmaceutical Economics and Policy | 2021-2025 | 6 | US 3 | 99.02 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 35 | US 8 | 95.75 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 94 | US 29 | 95.39 |
| Fatty Acid Research and Health | 2021-2025 | 56 | US 18 | 94.73 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 131 | US 31 | 96.83 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 86 | US 23 | 94.90 |
| Acute Myeloid Leukemia Research | 2021-2025 | 398 | US 205 | 96.44 |
| Acute Myocardial Infarction Research | 2021-2025 | 311 | US 77 | 96.00 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 180 | US 99 | 95.54 |
| Heart Failure Treatment and Management | 2021-2025 | 383 | US 134 | 95.34 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 153 | US 84 | 93.14 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 536 | US 188 | 92.56 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 550 | US 146 | 86.25 |
| Cardiac Health and Mental Health | 2021-2025 | 591 | US 184 | 86.37 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 140 | US 58 | 84.35 |
| GDF15 and Related Biomarkers | 2021-2025 | 110 | US 29 | 81.80 |
| Caveolin-1 and cellular processes | 2021-2025 | 70 | US 15 | 73.42 |
| Cardiovascular, Neuropeptides, and Oxidative Stress Research | 2021-2025 | 248 | US 29 | 64.33 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | 2021-2025 | 752 | US 266 | 65.18 |
| Apelin-related biomedical research | 2021-2025 | 370 | US 62 | 57.51 |
| Biomarkers in Disease Mechanisms | 2021-2025 | 552 | US 32 | 52.81 |
| Ginkgo biloba and Cashew Applications | 2021-2025 | 596 | US 49 | 46.63 |
| Macrophage Migration Inhibitory Factor | 2021-2025 | 596 | US 95 | 33.37 |
